@article{c2ff609208e74a2bb52c5efb8a395648,
title = "Breast cancer, version 4.2021 featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.",
author = "Gradishar, {William J.} and Moran, {Meena S.} and Jame Abraham and Rebecca Aft and Doreen Agnese and Allison, {Kimberly H.} and Blair, {Sarah L.} and Burstein, {Harold J.} and Chau Dang and Elias, {Anthony D.} and Giordano, {Sharon H.} and Goetz, {Matthew P.} and Goldstein, {Lori J.} and Hurvitz, {Sara A.} and Isakoff, {Steven J.} and Jankowitz, {Rachel C.} and Javid, {Sara H.} and Jairam Krishnamurthy and Marilyn Leitch and Janice Lyons and Jennifer Matro and Mayer, {Ingrid A.} and Joanne Mortimer and O'Regan, {Ruth M.} and Patel, {Sameer A.} and Pierce, {Lori J.} and Rugo, {Hope S.} and Amy Sitapati and Smith, {Karen Lisa} and Smith, {Mary Lou} and Hatem Soliman and Stringer-Reasor, {Erica M.} and Telli, {Melinda L.} and Ward, {John H.} and Wisinski, {Kari B.} and Young, {Jessica S.} and Burns, {Jennifer L.} and Rashmi Kumar",
note = "Funding Information: Ingrid A. Mayer, MD, Panel Member, has disclosed receiving consulting fees from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Genentech, Inc., GlaxoSmithKline, Immunomedics, Inc., Novartis Pharmaceuticals Corporation, Eli Lilly and Company, MacroGenics, Inc., Puma Biotechnology, and Seattle Genetics, Inc.; honoraria from AstraZeneca Pharmaceuticals LP, Genentech, Inc., and Novartis Pharmaceuticals Corporation; and grant/research support from Genentech, Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc. Funding Information: This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie. Publisher Copyright: {\textcopyright} 2021 Harborside Press. All rights reserved.",
year = "2021",
month = may,
doi = "10.6004/jnccn.2021.0023",
language = "English (US)",
volume = "19",
pages = "484--494",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",
}